ArticleCancer biology & therapy2019

Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).

Jiaxin Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.